surmount-1 tirzepatide non-diabetic obesity weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers Tirzepatide Mechanism of Weight Loss

DSIP promotes delta wave activity during deep sleep stages, enhancing the most restorative phase of sleep where physical recovery, immune function, and memory consolidation occur optimally

PMID: 29081890

Altogether, these important findings may pave the way to developing novel antiviral strategies for treating infectious liver disease

Hence, it is essential to take your healthcare provider onboard before including any new supplement into your diet or making any kind of lifestyle alterations, especially when you are dealing with certain health conditions or are pregnant

No, hot flushes are not listed among the common, uncommon, or rare side effects in the UK Summary of Product Characteristics for Mounjaro

Osteoarthritis with obesity is being studied because weight loss reduces mechanical joint stress and systemic inflammation